GCG and Stroke: Likewise, the LEADER trial concluded that a related GLP‐1 mimetic, namely, liraglutide, was beneficial in reducing the rate of non‐fatal myocardial infarction, stroke and first occurrence of death from cardiovascular causes (Marso, Daniels, et al., 2016).